LabCorp

CND Life Sciences is a medical diagnostics company focused on developing innovative tools for the diagnosis of neurodegenerative diseases, particularly synucleinopathies such as Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure. The company has introduced the Syn-One Test, an evidence-based diagnostic tool that detects, visualizes, and quantifies abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. This test provides medical professionals with a convenient, accurate, and minimally invasive method to confirm the presence of synucleinopathy in patients, addressing a critical need for reliable diagnostic options in the field of neurology.

Olaris is a biotechnology company focused on transforming disease diagnosis and treatment through its innovative CEREBRO platform, which integrates metabolomics and machine learning. Founded in 2013 and headquartered in Framingham, Massachusetts, Olaris aims to enhance precision medicine by utilizing the body’s natural communication systems to identify biomarkers essential for treatment responsiveness. Through its myOLARIS™ precision diagnostics pipeline, the company collaborates with healthcare providers to tailor therapeutic approaches, thereby optimizing patient outcomes and minimizing adverse effects. Olaris is dedicated to advancing personalized healthcare solutions that improve the efficacy of medical interventions.

BioReference Health - Laboratory Testing Businesses focused on oncology and oncology-related clinical testing services.

Percipio Health is a healthcare technology company that leverages artificial intelligence to enhance patient care. It provides a platform that integrates advanced computer vision software to monitor and assess patient health status. This technology enables clinicians and caregivers to maintain a comprehensive view of a patient's well-being and accurately identify medications. By offering AI-driven insights, Percipio Health empowers healthcare providers to make informed decisions, ultimately improving the quality of care delivered to patients.

Teal Health is dedicated to improving women's health by providing innovative solutions, starting with at-home cervical cancer screenings. The company has developed the first FDA-approved device that allows women to perform cervical cancer screenings in the comfort and privacy of their own homes. By simplifying the screening process, Teal Health aims to encourage timely screenings and promote early treatment, ultimately working towards the eradication of cervical cancer in the United States. The company's mission focuses on designing health solutions that cater to women's preferences and experiences, addressing the pressing issues in women's health with a commitment to empowerment and accessibility.

Geneoscopy, LLC is a diagnostics company based in Saint Louis, Missouri, that specializes in non-invasive colorectal cancer screening and gastrointestinal disease management. Founded in 2015, Geneoscopy has developed a platform technology that utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the downstream effects of cancer-causing DNA mutations. The company's diagnostic test aims to improve compliance with colorectal cancer screening, facilitate early-stage detection of neoplasms, and ultimately reduce morbidity and mortality associated with the disease. Additionally, Geneoscopy is exploring other applications of its technology for various gastrointestinal conditions, aiming to provide reliable alternatives to traditional invasive procedures like colonoscopy.

Praia Health is an innovative digital health company that focuses on enhancing the delivery of personalized health solutions for hospitals and their patients. The company's platform is designed to facilitate the digital transformation of health systems by streamlining and customizing health journeys. It connects patients with appropriate services, products, and resources, thereby creating comprehensive patient profiles that extend beyond traditional clinical records. This approach enables hospitals to sustain stronger relationships with their patients and provide more specialized care throughout their health experiences.

GLX Analytix is a biotechnology company focused on transforming healthcare through the integration of proprietary blood biomarkers and artificial intelligence. The company aims to facilitate early diagnosis and continuous monitoring of chronic diseases, thereby empowering patients to manage their health more effectively. By providing tools that enable clinicians to monitor disease progression and predict flare-ups, GLX Analytix enhances treatment plans and improves patient outcomes. As an Industrial Partner to Harvard Medical/Wyss Diagnostic Accelerator and a recipient of the Roche Future of Healthcare Award, GLX Analytix is recognized for its potential to significantly impact patient care and quality of life on a global scale.

PreciseDx is a specialized company focused on cancer risk stratification, providing patient-specific risk assessments through the analysis of morphological features. By leveraging artificial intelligence and its proprietary Morphology Feature Array™, PreciseDx develops disease-specific assays that enhance the understanding of a patient's risk profile and potential outcomes. This innovative approach allows clinical teams to gain valuable insights and actionable intelligence, facilitating more personalized treatment decisions. The company's expertise spans clinical modeling, patient phenotyping, image analysis, and the application of big data in real-world scenarios, ultimately aiming to improve patient outcomes and quality of life in cancer care and other diseases.

NOWDiagnostics, Inc. is a company based in Springdale, Arkansas, that specializes in the development and manufacturing of blood-based rapid diagnostic tests. Founded in 2013, the company offers innovative testing solutions that require only a single drop of blood, providing results within minutes. This approach empowers both patients and caregivers by enabling timely decision-making regarding healthcare. NOWDiagnostics' product line, ADEXUSDx, includes tests for various conditions such as pregnancy, cardiac events, and toxicology, all designed to be conducted in-home or in-clinic without the need for off-site laboratory processing. The company aims to reduce the waiting time for test results, enhancing the overall efficiency of medical diagnostics. NOWDiagnostics collaborates with strategic partners, including Zalgen Labs LLC, to expand its offerings in the diagnostic market.

Acclinate is a high-growth company that focuses on enhancing diversity and representation in genomic research and clinical trials through its digital health platform. By leveraging machine learning and predictive analytics, Acclinate automates the processes of identifying, educating, engaging, and retaining diverse participants for genomic studies. This approach not only empowers communities to take proactive steps towards better health but also helps biopharmaceutical research organizations reduce the overall costs associated with drug development. Through sustained engagement and AI-driven insights, Acclinate aims to transform the landscape of clinical research and improve health outcomes for underrepresented populations.

Phenomix Sciences is a biotechnology company founded in 2017 and headquartered in New York, United States. It specializes in the fields of metabolomics and genomics, focusing on developing healthcare solutions for personalized management of chronic diseases. The company has created a data analysis platform aimed at precision medicinal research for obesity management, which features a novel blood test and an AI-driven algorithm. This platform classifies the unique pathophysiological phenotype of patients with obesity, providing healthcare centers with tools and services that enhance the efficacy of obesity management while also reducing side effects and overall costs.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

Xcell Biosciences, Inc. is a San Francisco-based life science company founded in 2012, specializing in innovative technologies for cancer research and immunotherapy. The company has developed proprietary systems that capture, grow, and analyze cancer cells directly from patient blood samples, allowing for precise control over primary cell phenotype and function. This technology enhances the development and production of cell therapies, providing scientists with advanced tools for cell maintenance, expansion, and optimization. By supporting various primary cell types, including immune, stem, and tumor cells, Xcell Biosciences aims to improve predictive therapy development and clinical outcomes for patients undergoing immunotherapy.

Prolocor is a biotechnology company based in Philadelphia, PA, founded in 2020. It specializes in developing diagnostic tests aimed at assessing and managing cardiovascular disease risk. The company focuses on creating a precise method to quantify platelet FcγRIIa, which helps identify patients at varying risk levels for heart attacks, strokes, and cardiovascular-related deaths. Prolocor's tests utilize flow cytometry to measure the number of FcγRIIa molecules on platelets, enabling healthcare providers to optimize treatment strategies. This innovative approach aims to reduce complications such as bleeding and recurrent thrombotic events, enhancing patient care in cardiovascular health.

Advanced Animal Diagnostics, Inc. specializes in the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Founded in 2001 and based in Durham, North Carolina, the company offers innovative products such as the QScout Farm Lab, an analyzer system that detects infections before visible symptoms occur, and the QScout Milk Leukocyte Differential rapid test, which identifies and differentiates leukocytes in milk to facilitate early mastitis detection. Additionally, Advanced Animal Diagnostics provides the QuickSmear slide for animal research and the SCC+ System for timely mastitis diagnosis. The company's solutions focus on enhancing the management of disease states and improving the reproductive, nutritional, and overall health of production animals, serving veterinarians and livestock producers to promote healthier and more productive animal care.

HealthEC, LLC is a technology company that specializes in healthcare information exchange and population health management both in the United States and internationally. It provides a comprehensive Population Health Management platform that consolidates various essential elements of care management, including patient attribution, care coordination, and analytics tailored for payers, providers, and employers. HealthEC's offerings encompass a suite of solutions such as ACO in a Box, which integrates population management and patient engagement; transformation consulting; and the Physician Quality Reporting System that incentivizes quality reporting among professionals. Additionally, the company delivers Provider Management solutions, claims and beneficiary management, 3D analytics for actionable insights, and revenue cycle management. Founded in 1997 as IGI Health and rebranded to HealthEC in 2013, the company is headquartered in Edison, New Jersey, with additional offices in Indiana and India. Its diverse clientele includes hospitals, health systems, physician group practices, ACOs, health plans, and self-insured employers.

AOA, based in Boston, New York, and London, is a female-led company focused on developing innovative cancer diagnostics specifically for women's health. The company is dedicated to creating the first accurate early-stage liquid biopsy test for ovarian cancer, which aims to enhance clinical practices, reduce patient mortality, and offer cost savings for healthcare payers. Utilizing an artificial intelligence-enabled platform, AOA's technology analyzes tumor marker gangliosides to facilitate the early detection of ovarian cancer. This approach not only helps healthcare providers implement more effective treatment strategies but also ensures that patients can access life-saving treatments sooner and at a more affordable cost.

Baystate Health Foundation is an independent non-profit organization located in Springfield, Massachusetts. Established in 2000, it plays a crucial role in supporting the philanthropic efforts of Baystate Health, an integrated healthcare delivery system that serves nearly one million people in western Massachusetts. The foundation focuses on fundraising for healthcare-related activities and is dedicated to enhancing the services provided by Baystate Health and its tax-exempt, not-for-profit subsidiaries. It manages endowments and charitable donations to promote the health and well-being of the community, with its investments overseen by the executive management team. Through its initiatives, Baystate Health Foundation aims to improve healthcare access and quality for the populations it serves.

Evvy is a company focused on women's health, specializing in at-home vaginal microbiome tests aimed at closing the gender health gap. By utilizing metagenomic sequencing, Evvy's tests analyze individual symptoms and assess risks related to significant health issues. The company provides personalized reports that empower women with insights into their bodies, facilitating a better understanding of their health and promoting overall well-being.

Adela is a company focused on developing innovative technologies for the early detection of cancer and other serious health conditions through routine blood testing. Utilizing a genome-wide methylome enrichment platform, Adela captures and analyzes information from the entire methylome, effectively identifying and targeting highly informative methylated regions of the genome for sequencing. This approach enables the detection of minimal residual disease and aids in tumor classification using plasma cell-free DNA methylomes. Adela's technology is designed to assist healthcare professionals in cancer detection, as well as in prenatal diagnostics, cardiology, and the monitoring of immune responses. Through its advancements, Adela aims to improve diagnostic accuracy and patient outcomes in the realm of high-morbidity and high-mortality conditions.

Vital Bio is focused on transforming lab testing to make healthcare more accessible and personalized. The company develops advanced diagnostic technologies that integrate devices, software, and services to support patients in monitoring their health and managing diseases. By bridging the gap between diagnosis and treatment, Vital Bio aims to empower patients and healthcare providers alike, promoting proactive care and reducing disparities in health outcomes. The company's innovative approach seeks to enhance the overall healthcare experience, ensuring that individuals have greater control over their health management.

Prognos Health is a health tech company focused on healthcare analytics, offering a platform called prognosFACTOR. This innovative platform can quickly query billions of lab and health records from over 325 million de-identified patients, providing answers to clinically relevant healthcare questions in a fraction of the time traditionally required. Prognos Health allows clients to access HIPAA-compliant, patient-centric healthcare data through the Prognos Marketplace, facilitating a range of applications such as cohort design, patient journey studies, and health outcomes analysis. The company's clientele includes 25 of the top 30 pharmaceutical manufacturers and three of the top five health payers, highlighting its significant role in empowering precise decision-making throughout the healthcare landscape.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through the development of highly sensitive tests that identify and characterize circulating tumor cells (CTCs) using minimally invasive blood samples. Founded in 2008, the company’s platform enables the profiling of single-cell phenotypes and genotypes, providing detailed information on biomarker expression levels, morphologic characteristics, and genetic changes. Epic Sciences offers the Oncotype DX AR-V7 Nucleus Detect test specifically for patients with metastatic castration-resistant prostate cancer, as well as biopharma solutions. The company collaborates with biotechnology and pharmaceutical firms, major cancer centers, and renowned research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and guide treatment decisions.

Mercy BioAnalytics is a biotechnology company based in Natick, Massachusetts, founded in 2018 by Paul Blavin and Joseph Sedlak. The company focuses on improving cancer outcomes through early detection using a novel liquid biopsy assay platform. This platform analyzes tumor-derived extracellular vesicles, which are plentiful in blood and contain critical information about their parent cells. By leveraging these extracellular vesicles, Mercy BioAnalytics aims to enable the detection of various types of cancer at the earliest stages, thus improving the chances of successful treatment and patient survival.

Kiyatec, LLC is a biotechnology company specializing in the development of advanced 3D cell-based assays aimed at enhancing preclinical drug discovery and clinical therapy applications. Founded in 2005 and based in Greenville, South Carolina, Kiyatec employs its proprietary 3DKUBE technology platform to create functional 3D models using patients' own living tumor cells. This innovative approach allows for the evaluation of various cancer therapies, providing insights into drug toxicity and efficacy before clinical trials. The company offers a range of services, including drug response profiling, predictions of patient responses to therapies, and cell-based assays for oncologists. Additionally, Kiyatec collaborates with biopharma clients on standard and custom assays and conducts research funded by the National Cancer Institute to develop 3D cell culture models for several types of cancer, such as breast cancer, glioblastoma, and lung cancer. By modeling complex human biology and simulating in vivo conditions, Kiyatec aims to improve treatment selection for cancer patients and support the development of medical devices and therapeutic drugs.

Clinical Outreach Laboratory Services provides all medical and clinical trials.

Prolocor is a biotechnology company based in Philadelphia, PA, founded in 2020. It specializes in developing diagnostic tests aimed at assessing and managing cardiovascular disease risk. The company focuses on creating a precise method to quantify platelet FcγRIIa, which helps identify patients at varying risk levels for heart attacks, strokes, and cardiovascular-related deaths. Prolocor's tests utilize flow cytometry to measure the number of FcγRIIa molecules on platelets, enabling healthcare providers to optimize treatment strategies. This innovative approach aims to reduce complications such as bleeding and recurrent thrombotic events, enhancing patient care in cardiovascular health.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through the development of highly sensitive tests that identify and characterize circulating tumor cells (CTCs) using minimally invasive blood samples. Founded in 2008, the company’s platform enables the profiling of single-cell phenotypes and genotypes, providing detailed information on biomarker expression levels, morphologic characteristics, and genetic changes. Epic Sciences offers the Oncotype DX AR-V7 Nucleus Detect test specifically for patients with metastatic castration-resistant prostate cancer, as well as biopharma solutions. The company collaborates with biotechnology and pharmaceutical firms, major cancer centers, and renowned research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and guide treatment decisions.

Circuit Clinical is an integrated research organization that has emerged from the experience of a physician engaged in clinical research within a private practice. Established in 2015, the company aims to enhance the way clinical research is conducted by emphasizing physician and participant engagement. Circuit Clinical leverages a network of over 1 million patients, utilizing direct HIPAA/FDA-compliant Electronic Medical Record reviews to identify motivated participants. The organization provides research services that facilitate access to clinical research, guiding both experienced and novice community physicians and their patients through each step of the clinical research process. Through its technology products and focus on participant and physician experience, Circuit Clinical seeks to improve research site quality and patient safety, creating a more efficient pathway for clinical research.

Getlabs, Inc. is a digital health company founded in 2018 and based in Santa Monica, California, specializing in at-home diagnostics. The platform enables healthcare organizations to send mobile phlebotomists to patients' homes for the collection of lab tests, vital signs, and advanced diagnostics. By facilitating these at-home appointments, Getlabs enhances patient adherence and addresses gaps in care through its nationwide, same-day service. The company aims to improve access to essential diagnostic services, effectively bridging the divide between virtual and in-person healthcare. With significant backing from major diagnostic laboratories, Getlabs is committed to expanding access to diagnostics for all patients, thereby supporting better health outcomes.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

PetDx is a San Diego-based molecular diagnostics company that specializes in the early detection of cancer in pets through innovative liquid biopsy technology. The company's main product, OncoK9, is a first-in-class multi-cancer early detection test that allows veterinarians to identify cancer in dogs using a simple blood draw. By utilizing advanced genomic analysis, including next-generation sequencing and proprietary bioinformatics algorithms, PetDx empowers veterinarians to enhance the care they provide to canine patients. The company's focus on non-invasive testing and customized assays positions it at the forefront of veterinary oncology, aiming to revolutionize how cancer is detected, characterized, and managed in pets.

Toxikon Corp., founded in 1977 by Dr. Laxman Desai, is a preclinical contract research organization based in Bedford, Massachusetts. Initially established as Cambridge Diagnostics, the company has a long history of advancing innovations in the pharmaceutical, biotechnology, and medical device industries. Toxikon offers a comprehensive range of in vivo, in vitro, and analytical testing services that facilitate the progression of therapies from initial concept through research, development, trials, and commercialization. Over the years, Toxikon has expanded its capabilities significantly, including the acquisition of the former American Biogenics facility and the addition of a neighboring laboratory space, which enhances its capacity for bioanalytical support and large animal models. With over three decades of experience, Toxikon is dedicated to helping clients navigate the complexities of regulatory approval processes, ensuring that products reach the market efficiently and effectively.

Geneoscopy, LLC is a diagnostics company based in Saint Louis, Missouri, that specializes in non-invasive colorectal cancer screening and gastrointestinal disease management. Founded in 2015, Geneoscopy has developed a platform technology that utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the downstream effects of cancer-causing DNA mutations. The company's diagnostic test aims to improve compliance with colorectal cancer screening, facilitate early-stage detection of neoplasms, and ultimately reduce morbidity and mortality associated with the disease. Additionally, Geneoscopy is exploring other applications of its technology for various gastrointestinal conditions, aiming to provide reliable alternatives to traditional invasive procedures like colonoscopy.

GeneCentric Diagnostics is engaged in the development and commercialization of molecular diagnostic tests aimed at assisting oncologists and patients in cancer treatment. The company has established two primary platform technologies: The Lung Subtype Platform (LSP), which classifies lung cancer patients into specific subtypes to guide therapeutic choices, and the Hypoxia Signature, designed to identify patients likely to benefit from anti-angiogenesis therapies. The LSP has been licensed to Laboratory Corporation of America Holdings and is available as HistoPlusSM: Lung Cancer through its Integrated Oncology division. GeneCentric's innovative partnership model facilitates the translation of significant cancer research into diagnostics that are clinically adopted by pathologists and clinicians. Incorporated in 2011 and located in Durham, North Carolina, GeneCentric aims to enhance treatment outcomes by enabling more precise targeting of therapeutic compounds based on tumor biology.

Xcell Biosciences, Inc. is a San Francisco-based life science company founded in 2012, specializing in innovative technologies for cancer research and immunotherapy. The company has developed proprietary systems that capture, grow, and analyze cancer cells directly from patient blood samples, allowing for precise control over primary cell phenotype and function. This technology enhances the development and production of cell therapies, providing scientists with advanced tools for cell maintenance, expansion, and optimization. By supporting various primary cell types, including immune, stem, and tumor cells, Xcell Biosciences aims to improve predictive therapy development and clinical outcomes for patients undergoing immunotherapy.

Ovia Health is a digital healthcare company that provides a comprehensive maternity and family benefits solution, enhancing support for women and families during their parenthood journey. Originally known as Ovuline, the company offers a suite of mobile applications, including Ovia Fertility and Ovia Pregnancy, which deliver personalized information and resources related to fertility, pregnancy, and parenting. By empowering women with customized health insights, Ovia Health enables them to take control of their reproductive health and navigate the complexities of starting a family with confidence. The company's focus on integrating healthcare into everyday life positions it as a valuable resource for families seeking to improve their well-being throughout the parenting experience.

OmniSeq is a molecular diagnostic laboratory based in Buffalo, New York, founded in 2015 as an innovation of Roswell Park Cancer Institute. The company specializes in providing actionable tumor-profiling information to physicians and their patients, aiming to identify the most suitable drug or clinical trial for each individual. OmniSeq offers New York State CLEP-approved assays, including the OmniSeq Comprehensive, a 144-gene next-generation sequencing assay that detects nearly all known genetic alterations tied to FDA-approved targeted therapies or genotype-directed clinical trials. The company also focuses on enhancing diagnostics for immuno-oncology therapy selection. By leveraging advanced molecular therapy technologies, including a proprietary algorithm that minimizes false positives, OmniSeq strives to improve access to cancer treatment options through precise and comprehensive molecular profiling.

Biospectal is a remote patient monitoring and biosensing software company that has developed the OptiBP smartphone app, which allows users to measure and monitor blood pressure with medical-grade accuracy using their smartphones. The app utilizes the phone's built-in camera to optically measure blood flow from the user's fingertip, providing results in approximately 20 seconds, which is significantly faster than traditional blood pressure cuffs. Biospectal's proprietary algorithms interpret the captured data to deliver accurate blood pressure readings. The OptiBP app is currently available in public beta for Android users in several countries, including the United States, United Kingdom, France, Germany, Spain, and Switzerland. This innovative approach enables users to perform blood pressure measurements anytime and anywhere without the need for additional devices or accessories.

PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Advanced Animal Diagnostics, Inc. specializes in the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Founded in 2001 and based in Durham, North Carolina, the company offers innovative products such as the QScout Farm Lab, an analyzer system that detects infections before visible symptoms occur, and the QScout Milk Leukocyte Differential rapid test, which identifies and differentiates leukocytes in milk to facilitate early mastitis detection. Additionally, Advanced Animal Diagnostics provides the QuickSmear slide for animal research and the SCC+ System for timely mastitis diagnosis. The company's solutions focus on enhancing the management of disease states and improving the reproductive, nutritional, and overall health of production animals, serving veterinarians and livestock producers to promote healthier and more productive animal care.

Vectra is a non-invasive, blood-based test that analyzes 12 biomarkers to measure RA disease activity. It combines those measures to generate an easy-to-understand score, which indicates the severity of RA inflammation and how well current treatments are working. It also can predict potential, future joint damage. This enables the 5,000 practicing rheumatologists in the U.S. to provide targeted treatment and adjust existing treatments to better manage RA symptoms

TrakCel Ltd. is a technology company based in Cardiff, United Kingdom, specializing in integrated solutions for the cell therapy supply chain, specifically for autologous and allogeneic therapies. Founded in 2012, TrakCel offers a comprehensive Cell Orchestration Platform, a cloud-based software solution that streamlines the development of cell and gene therapies. This platform enables users to collate, track, and document essential program information, enhancing efficiency and compliance throughout various stages of therapy development. TrakCel's technology supports medical centers, logistics providers, manufacturers, and therapy sponsors by facilitating regulatory audits and addressing the data management, reporting, and analysis needs of clinical trials. By providing a scalable and validated platform, TrakCel aims to modernize and optimize the processes involved in cell and gene therapy, thereby reducing the time, cost, and risks associated with traditional paper-based systems.

Presage Biosciences, Inc. is an oncology company based in Seattle, Washington, that focuses on enhancing drug development and clinical trials through innovative technology. Founded in 2008, the company has developed the CIVO arrayed microinjection platform, which allows for the simultaneous assessment of multiple drugs or drug combinations directly within a patient's tumor. This method provides insights into drug efficacy, resistance, and potential synergies in the tumor's native microenvironment, thereby overcoming limitations associated with systemic drug administration. By using this clinical surrogate approach, Presage enables drug developers to identify ineffective compounds early in the process, ultimately streamlining the development of effective cancer treatments. The technology also facilitates the identification of drug targets and effective combinations, allowing for more accurate measurement of therapeutic responses.

Circuit Clinical is an integrated research organization that has emerged from the experience of a physician engaged in clinical research within a private practice. Established in 2015, the company aims to enhance the way clinical research is conducted by emphasizing physician and participant engagement. Circuit Clinical leverages a network of over 1 million patients, utilizing direct HIPAA/FDA-compliant Electronic Medical Record reviews to identify motivated participants. The organization provides research services that facilitate access to clinical research, guiding both experienced and novice community physicians and their patients through each step of the clinical research process. Through its technology products and focus on participant and physician experience, Circuit Clinical seeks to improve research site quality and patient safety, creating a more efficient pathway for clinical research.

Dorsata, Inc. is a healthcare technology company that specializes in providing an online platform for the development, sharing, and application of clinical care pathways. Founded in 2011 and headquartered in Arlington, Virginia, Dorsata's platform enhances collaboration among healthcare providers by enabling them to create and utilize defined workflows for efficient decision-making, documentation, and order entry. By leveraging clinician-developed care pathways, the company aims to improve healthcare quality and reduce costs. Additionally, Dorsata has developed a prenatal record platform that allows providers to manage electronic health records effectively, offering a user-friendly experience and a rules engine that helps create tailored care plans for patients throughout their pregnancy.

PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Navigating Cancer, Inc., established in 2008 and headquartered in Seattle, Washington, operates a Web-based patient care portal designed specifically for cancer programs. This platform enables cancer survivors to receive, organize, and understand their medical information, track their health, and engage with healthcare professionals. It also offers educational resources on various types of cancer and chemotherapy treatments. The portal aims to simplify practice workflows for healthcare providers, facilitate patient-centered care, and improve overall outcomes by empowering patients through technology.

Weavr Health is a healthcare technology company focused on transforming blood collection practices by enabling patients to collect clinical-grade blood samples in their own homes. The company has developed a self-collection device that allows average users to perform this task without the assistance of a phlebotomist. By integrating complex sample processing steps into its devices, Weavr Health simplifies diagnostic testing, making it more accessible and efficient at the point of care. This innovative approach aims to enhance patient experience and streamline healthcare delivery.

Sandstone Diagnostics is a Bay Area biotech company developing instruments and consumables for point-of-care medical testing. Sandstone’s lead product, Trak, is a consumer semen analysis platform that provides a simple and accurate way to monitor sperm quality from the comfort of home. Trak is a tool for men to take charge of their fertility, boost their sperm quality, and improve their chances of conception. Sandstone was co-founded in 2012 by Ph.D. scientists developing medical technologies for national defense applications at Sandia National Laboratories.

Sandstone Diagnostics, Inc. is a technology and healthcare company based in Pleasanton, California, that specializes in developing medical products and research tools focused on male fertility management. Founded in 2012, the company manufactures innovative devices such as the Torq ZDrive, which separates blood cells from liquid plasma at the point of collection, and the Torq Microvolume Rotor, a tool for remote blood sampling that facilitates comprehensive diagnostic testing. Additionally, Sandstone offers the Trak fertility system, which includes an engine, a disposable test plate, a sample collection cup, and a dropper, enabling men to monitor their sperm quality and take proactive steps toward improving their fertility. The accompanying Trak mobile application allows users to track their fertility data over time, identify potential fertility issues, and enhance their chances of conception. Sandstone Diagnostics aims to empower couples to manage their reproductive health in the comfort and privacy of their homes.

Kiyatec, LLC is a biotechnology company specializing in the development of advanced 3D cell-based assays aimed at enhancing preclinical drug discovery and clinical therapy applications. Founded in 2005 and based in Greenville, South Carolina, Kiyatec employs its proprietary 3DKUBE technology platform to create functional 3D models using patients' own living tumor cells. This innovative approach allows for the evaluation of various cancer therapies, providing insights into drug toxicity and efficacy before clinical trials. The company offers a range of services, including drug response profiling, predictions of patient responses to therapies, and cell-based assays for oncologists. Additionally, Kiyatec collaborates with biopharma clients on standard and custom assays and conducts research funded by the National Cancer Institute to develop 3D cell culture models for several types of cancer, such as breast cancer, glioblastoma, and lung cancer. By modeling complex human biology and simulating in vivo conditions, Kiyatec aims to improve treatment selection for cancer patients and support the development of medical devices and therapeutic drugs.

Mission Bio, Inc. is a biotechnology company focused on advancing the study of cellular heterogeneity through its innovative Tapestri Platform, which is the first single-cell multi-omics platform. This platform allows for the simultaneous analysis of genotype and phenotype from individual cells, enabling precise detection of variations in disease progression and treatment responses. Utilizing proprietary microfluidic droplet technology, Mission Bio provides targeted solutions for high-impact applications in fields such as oncology, hematology, and genome editing. The company also offers Tapestri Designer, a cloud-based tool for creating custom single-cell DNA panels, enhancing its capabilities in research and clinical settings. Founded in 2011 and based in South San Francisco, California, Mission Bio was previously known as Torrent Bio, Inc. before rebranding in 2013.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

MC10, Inc. is a company that specializes in developing wearable medical sensors designed to collect clinical-grade biometric and physiological data. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of innovative products, including BioStamp nPoint for vital signs and activity monitoring, Kintinuum for orthopedic rehabilitation, WiSP for cardiac monitoring, and BioStampMD, a conformal sensor that gathers both objective and subjective health data. MC10 employs advanced flexible electronics technology, allowing its devices to bend and stretch with the body, ensuring comfort and ease of use. The company focuses on enhancing human capabilities and improving health insights through discreet, location-specific sensing that captures real-world data on muscle activation and movement, with applications extending across various sectors including sports, military, and energy.

OmniSeq is a molecular diagnostic laboratory based in Buffalo, New York, founded in 2015 as an innovation of Roswell Park Cancer Institute. The company specializes in providing actionable tumor-profiling information to physicians and their patients, aiming to identify the most suitable drug or clinical trial for each individual. OmniSeq offers New York State CLEP-approved assays, including the OmniSeq Comprehensive, a 144-gene next-generation sequencing assay that detects nearly all known genetic alterations tied to FDA-approved targeted therapies or genotype-directed clinical trials. The company also focuses on enhancing diagnostics for immuno-oncology therapy selection. By leveraging advanced molecular therapy technologies, including a proprietary algorithm that minimizes false positives, OmniSeq strives to improve access to cancer treatment options through precise and comprehensive molecular profiling.

The Recovery Platform is a medical enterprise dedicated to enhancing medication-assisted treatment (MAT) for substance use disorders. It provides a specialized platform that supports both physicians and patients in adhering to treatment protocols. The platform offers a comprehensive suite of tools designed to monitor patient compliance, track progress, and facilitate telehealth communication, as well as manage scheduling. By streamlining these processes, the Recovery Platform aids physicians in guiding their patients through the transition from opioid dependence to recovery, ensuring that compliance requirements are effectively managed while promoting best practices in treatment.

Chiltern International Limited is a prominent contract research organization that specializes in clinical development and scientific services for the pharmaceutical and biotechnology sectors. The company offers a comprehensive range of services, including early and late-phase clinical development, biostatistics, and medical and regulatory affairs. Chiltern serves various specialty areas within the biopharmaceutical and medical device industries, utilizing diverse engagement models to meet the specific needs of its clients. In addition to its clinical services, Chiltern also provides resourcing solutions to support the operational requirements of its partners. Through its expertise and collaborative technologies, the company plays a crucial role in advancing clinical research and development.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

PAML is a healthcare solutions company with a focus in diagnostics. It proudly serve physicians, hospitals, members of the community, employers, and other allied health professionals.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, specializing in women's health diagnostics. Founded in 2008, it focuses on developing innovative diagnostic tests that aid in the early prediction of a woman's individualized risk for complications during pregnancy, including premature birth, preeclampsia, and gestational diabetes. Sera's proprietary proteomics and bioinformatics platform enables the discovery and commercialization of blood-based biomarker tests, which provide critical information to healthcare providers. Notably, the company's PreTRM® Test assesses the risk of spontaneous premature delivery, facilitating timely interventions for at-risk patients. By addressing the healthcare challenges associated with pregnancy complications, Sera aims to enhance maternal and neonatal health while reducing overall healthcare costs.

YourBio Health is focused on transforming the blood sampling and testing process by creating innovative products that enhance the interface between diagnostic medicine and healthcare consumers. The company has developed a unique blood collection device that allows for convenient and virtually painless blood testing. Utilizing its proprietary Touch Activated Phlebotomy technology, this push-button device can be applied to the upper arm, enabling individuals to collect their blood with a simple press of a button. This one-step process is designed to eliminate barriers to acquiring critical diagnostic information, facilitating improved diagnoses and health outcomes. By making diagnostic testing accessible almost anywhere, YourBio Health aims to empower patients in their healthcare journey and enhance the overall experience for both patients and clinicians.

ClearPath Diagnostics is a pathologist-owned tissue pathology and cytology practice based in Syracuse, New York. Founded in 1975, the company specializes in providing a range of diagnostic services to healthcare providers and their patients across the United States. Its offerings include cytology and pathology services, as well as ancillary testing such as the Digene Hybrid Capture 2 for human papillomavirus (HPV), testing for gonorrhea and chlamydia, and immunohistochemistry. ClearPath also conducts frozen section analysis and provides in situ hybridization services to detect HPV and assess Her-2/neu gene amplification in breast cancer. Additionally, the company offers triple testing to identify vaginitis pathogens and Vysis UroVysion testing for the non-invasive evaluation of bladder cancer. Through its comprehensive diagnostic capabilities, ClearPath Diagnostics plays a vital role in enhancing patient care and treatment outcomes.

Sequenom, Inc. is a life sciences company that specializes in developing and commercializing molecular diagnostics testing services focused on women's health and oncology. The company offers a range of laboratory-developed tests (LDTs), including the MaterniT21 PLUS, a noninvasive prenatal test (NIPT) for detecting fetal chromosomal abnormalities, and the VisibiliT LDT, which assesses the relative amounts of chromosomal material in maternal blood samples. Sequenom also provides the MaterniT21 GENOME test for identifying genomic deletions or duplications, as well as the HerediT cystic fibrosis carrier screening test and the SensiGene fetal Rhesus D test. Additionally, the company offers microarray testing under the NextView brand and various carrier screening tests for genetic disorders under the HerediT brand. Founded in 1994 and headquartered in San Diego, California, Sequenom serves physicians and clinical laboratories, and it has established collaborations to enhance its genetic analysis capabilities. As of September 2016, Sequenom operates as a subsidiary of Laboratory Corporation of America Holdings.

Emulate, Inc. is a biotechnology company specializing in organs-on-chips technology that emulates human biology to enhance the understanding of diseases, medicines, chemicals, and food impacts on human health. The company develops organ-chips that replicate normal organ functions as well as various disease states, primarily targeting the lung, intestine, liver, and skin. Emulate's innovative human emulation system provides researchers with advanced in vitro models that offer more precise and detailed predictions of human responses compared to traditional experimental methods, such as cell culture or animal testing. The company serves a diverse range of markets, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic research. Founded in 2013 and based in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. before rebranding in July 2014.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

Calif.-based laboratory firm

Safe Food International (SFI) is an organization headquartered in Washington, D.C., dedicated to enhancing global food safety. It collaborates with consumer organizations worldwide to address critical food safety issues. SFI's initiatives focus on ensuring that national food safety programs are effective in tackling common challenges, such as the approval of food products before consumption or export, and in preventing intentional contamination of food supplies. Through awareness programs, SFI aims to promote safer food practices and advocate for stronger food safety standards across different regions.

Ativa Medical Corporation is a medical device manufacturing company based in Saint Paul, Minnesota, founded in 2008. The company specializes in developing and commercializing point of care testing medical diagnostics products aimed at decentralized healthcare settings. Ativa Medical focuses on providing rapid diagnostic test results for critical hematology and clinical chemistry tests, utilizing advanced microfluidics technology. Its product offerings include analyzers and disposable test cards designed for trauma, pediatric, oncology, and geriatric patients. These products cater to various healthcare environments, including hospital departments, physician's offices, and remote healthcare clinics, enhancing the speed and accessibility of medical diagnostics.

Bode Technology Group, Inc. specializes in human DNA analysis and innovative collection products primarily for law enforcement and identification markets. The company offers a comprehensive range of services, including high-throughput DNA testing, casework analysis, missing person identification, and databanking of convicted offenders and arrestees. Bode's patented DNA collection systems are utilized globally for gathering DNA from various sources, including crime scenes and familial relationships for genealogy purposes. Their teams of analysts and researchers continuously explore advanced methodologies and technologies to enhance the analysis of challenging samples, such as bones and aged tissue. Additionally, Bode provides customized consulting, training, and validation services, reinforcing its commitment to supporting law enforcement agencies and state governments in their forensic endeavors.

Vivify Health Inc. is a digital health company based in Plano, Texas, founded in 2009. It operates a cloud-based, device-agnostic platform that facilitates home-based remote monitoring, connecting healthcare providers with patients through consumer electronics. This innovative platform aims to reduce hospital readmissions and overall healthcare costs by enabling automatic remote biometric data collection and delivering tailored care plans. Vivify Health also offers a range of personal health devices, including tablets, weight scales, and pulse oximeters, to enhance patient engagement and support virtual interactions between patients and healthcare professionals. The company is a subsidiary of Optum, Inc. and has established a strategic alliance with AT&T to further its mission of improving population health and patient satisfaction.

Covance Inc. is a leading provider of contract research services focused on the pharmaceutical, biotechnology, and medical device industries. Established in 1987 and headquartered in Princeton, New Jersey, the company offers a comprehensive suite of early- and late-stage development services, including preclinical and clinical pharmacology, biomarker services, and full management of Phase II and III clinical studies. Additionally, Covance provides laboratory testing services to the chemical, agrochemical, and food industries, positioning itself as a market leader in toxicology, central laboratory services, and clinical trial management. The company is known for its extensive experience and specialized expertise, having contributed to the development of the top 50 prescription drugs available today. As part of Laboratory Corporation of America Holdings, Covance is dedicated to advancing healthcare by helping clients reduce the time and costs associated with drug development through high-quality nonclinical, clinical, and commercialization services.

LipoScience is a Raleigh, North Carolina-based company specializing in personalized diagnostics through the use of nuclear magnetic resonance (NMR) technology. The company has developed the NMR LipoProfile test, its flagship diagnostic tool, which quantitatively measures low density lipoprotein particles (LDL-P) in blood samples. This test provides physicians and patients with critical information to tailor heart disease risk management effectively. Since its inception, LipoScience has seen significant adoption, with over 8 million NMR LipoProfile tests ordered to date.

YourBio Health is focused on transforming the blood sampling and testing process by creating innovative products that enhance the interface between diagnostic medicine and healthcare consumers. The company has developed a unique blood collection device that allows for convenient and virtually painless blood testing. Utilizing its proprietary Touch Activated Phlebotomy technology, this push-button device can be applied to the upper arm, enabling individuals to collect their blood with a simple press of a button. This one-step process is designed to eliminate barriers to acquiring critical diagnostic information, facilitating improved diagnoses and health outcomes. By making diagnostic testing accessible almost anywhere, YourBio Health aims to empower patients in their healthcare journey and enhance the overall experience for both patients and clinicians.

Stateless Networks Inc. specializes in providing performance infrastructure and networking solutions tailored for enterprises, service providers, and the federal government. Founded in 2012 and headquartered in San Francisco, the company develops innovative software such as the Stateless AutoWare SDN Fabric Manager, which enhances network management through server-class monitoring capabilities. This technology accelerates deployments, improves system resilience, automates administrative tasks, and facilitates rapid recovery after equipment failures. By leveraging a combination of deep network understanding and advanced distributed systems, Stateless Networks aims to transform network operations for software-centric environments. The company collaborates with leading network and infrastructure vendors to deliver solutions that optimize performance and visibility in enterprise data centers.

Flatiron Health, Inc. is a healthcare technology company dedicated to enhancing cancer research and patient care through advanced data integration and analytics. The firm develops OncologyCloud, a comprehensive platform that consolidates disparate healthcare information systems to provide insights into patient populations. This platform enables cancer care providers and life sciences companies to analyze treatment patterns, monitor adherence to clinical guidelines, and facilitate real-time patient matching to clinical trials. Additionally, Flatiron offers OncoCloud, a software solution for community oncology practices, and tools like Flatiron Assist and OncoEMR, which support clinical decision-making and compliance with oncology care models. Established in 2012 and headquartered in New York, Flatiron Health collaborates with over 280 community cancer practices, prominent academic research centers, and leading oncology companies, positioning itself as a key player in the oncology data landscape. The company operates as a subsidiary of Roche Holding AG.

SynapDx is a diagnostic company based in Lexington, Massachusetts, focused on providing laboratory testing services aimed at the early detection of autism spectrum disorders (ASDs) in children. Established by Stanley Lapidus, the company develops blood-based diagnostic tests that leverage insights from experts in ASD and gene expression. These tests are designed to assist healthcare providers in identifying early symptoms of autism, addressing the need for timely intervention in a condition that affects approximately 1 in 110 children in the United States. Through its innovative approach, SynapDx aims to enhance the diagnostic process for developmental disorders and improve outcomes for affected children and their families.

SynapDx is a diagnostic company based in Lexington, Massachusetts, focused on providing laboratory testing services aimed at the early detection of autism spectrum disorders (ASDs) in children. Established by Stanley Lapidus, the company develops blood-based diagnostic tests that leverage insights from experts in ASD and gene expression. These tests are designed to assist healthcare providers in identifying early symptoms of autism, addressing the need for timely intervention in a condition that affects approximately 1 in 110 children in the United States. Through its innovative approach, SynapDx aims to enhance the diagnostic process for developmental disorders and improve outcomes for affected children and their families.

Flatiron Health, Inc. is a healthcare technology company dedicated to enhancing cancer research and patient care through advanced data integration and analytics. The firm develops OncologyCloud, a comprehensive platform that consolidates disparate healthcare information systems to provide insights into patient populations. This platform enables cancer care providers and life sciences companies to analyze treatment patterns, monitor adherence to clinical guidelines, and facilitate real-time patient matching to clinical trials. Additionally, Flatiron offers OncoCloud, a software solution for community oncology practices, and tools like Flatiron Assist and OncoEMR, which support clinical decision-making and compliance with oncology care models. Established in 2012 and headquartered in New York, Flatiron Health collaborates with over 280 community cancer practices, prominent academic research centers, and leading oncology companies, positioning itself as a key player in the oncology data landscape. The company operates as a subsidiary of Roche Holding AG.

Medtox Scientific operates a SAMHSA-certified drug testing laboratory, a CAP and CLIA-certified clinical laboratory, and an FDA-registered diagnostic division. The company provides comprehensive laboratory and diagnostic testing services, including medical drug monitoring, pain management, clinical toxicology, therapeutic drug monitoring, emergency toxicology, pediatric lead testing, forensic toxicology, and employment drug testing. Medtox Scientific is committed to delivering excellent customer service, ensuring efficient and effective operation of clients' testing programs. The company serves a diverse range of clients, including physician offices, corporations, clinics, health organizations, and government agencies, with a focus on building strong relationships and being responsive to client needs.

Clearstone Central Laboratories is the largest and most experienced private company.

Orchid Cellmark Ltd. provides genotyping and DNA testing services for forensic, human identity testing, and agricultural applications.

Sanofi Genzyme is the specialty care global business unit of Sanofi, primarily dedicated to addressing the challenges posed by rare diseases, multiple sclerosis, immunology, and oncology. Established in 1981 as Genzyme in Boston, the company grew to become a major player in biotechnology, known for pioneering treatments for rare genetic disorders. In 2011, Genzyme was integrated into Sanofi, enhancing its capabilities in developing therapies for complex conditions that are often difficult to diagnose and treat. Sanofi Genzyme emphasizes a patient-centered approach, collaborating closely with healthcare providers and patient communities to advance new therapies. Over the years, its focus has expanded beyond rare diseases to include significant contributions in multiple sclerosis, oncology, and immunology, reflecting a commitment to innovation and improving patient outcomes across diverse therapeutic areas.

Genzyme Genetics is an industry leading provider of reproductive and oncology testing in the United States.

DCL Medical Laboratories, Inc. is a provider of consultative laboratory testing solutions that specializes in anatomic and molecular pathology services. The company offers a range of testing options including diagnostic cytopathology, histopathology, and immunohistochemistry, along with a selection of antibodies for biomarker analysis. DCL Medical Laboratories also caters to clinical trials clients and provides reference testing services for hospitals and other laboratories, with a particular emphasis on women's health. Its testing portfolio includes ThinPrep Pap test processing and screening, HPV molecular testing, chlamydia and gonorrhea testing, and cystic fibrosis carrier screening for pre-conceptual and prenatal assessments. Serving the medical industry across the United States, DCL Medical Laboratories is dedicated to delivering high-quality diagnostic services tailored to meet the needs of its clients.

Monogram Biosciences is a leading developer of innovative products aimed at improving the treatment of infectious diseases, cancer, and other serious health conditions. The company specializes in molecular diagnostics and offers products such as Trofile, an assay that determines the tropism of a patient's HIV, facilitating personalized treatment options. Additionally, Monogram provides VeraTag technology, which enhances the development of targeted therapeutics. The company's solutions cater to healthcare providers and pharmaceutical companies, contributing to advancements in precision medicine and improving patient outcomes.

Tandem Labs is a bioanalytical contract research organization based in Salt Lake City, Utah, founded in 1995. It specializes in providing comprehensive support to pharmaceutical, biopharmaceutical, and biotechnology companies throughout their clinical and preclinical drug development programs. Tandem Labs offers a wide range of services, including mass spectrometry and immunochemistry, to facilitate bioanalytical studies. Its capabilities encompass GLP bioanalytical services such as method development and validation, clinical and preclinical sample analysis, and pharmacokinetic analysis. Additionally, the organization provides rapid turnaround non-GLP discovery services and specialized immunoanalytical testing. In 2008, Tandem Labs was acquired by LabCorp, further enhancing its position in the industry.

DSI Laboratories is an operator of a medical laboratory. it is a full-service medical reference and toxicology laboratory that offers clinical testing, histology, chemistry, cytology, microbiology, and molecular medicine testing services.

Litholink Corp is a clinical laboratory based in Chicago, Illinois, specializing in kidney disease management. The company offers 24-hour urine testing services aimed at kidney stone prevention, providing accurate test results and personalized treatment recommendations for patients. Litholink's national infrastructure supports seamless integration of its services, ensuring high levels of customer support and convenience for clients managing their laboratory needs.

Esoterix is a laboratory services company that specializes in high-quality scientific testing and exceptional customer service. The company offers a range of assays and profiles through its facilities located in the United States and Western Europe. In addition to laboratory testing for physician specialists, Esoterix provides clinical trial services and various support services, including information technology, managed care, and billing. Its commitment to innovation is evident in the development of new products designed to meet the evolving needs of the healthcare sector.

US Pathology Labs provider of anatomic pathology and oncology testing services with a focus on the outpatient market.

Dianon Pathology offers a broad array of testing procedures, combining the expertise of an academic-based center with the personal service of a local pathologist. Their services include dermatopathology, gastrointestinal pathology, and uropathology.

Dynacare is an independent clinical laboratory that provides a range of testing services to the healthcare sector in select regions of the United States and Canada. The company operates 26 central laboratories, including two that focus on esoteric testing, along with 115 rapid response labs and 302 patient service centers across 21 states and two Canadian provinces. Dynacare specializes in the clinical laboratory testing of body fluids, tissues, and other specimens, including human cells and molecular diagnostics. By offering diverse diagnostic lab services, the company aims to meet the needs of its clients with competitive pricing.

Path Lab also has cooperative testing arrangements with a number of area hospitals to enhance service levels and optimize the use of local testing capacity.

ViroMed Laboratories is an FDA-registered laboratory specializing in infectious disease testing. As part of LabCorp's Specialty Testing Group, the company offers a range of laboratory testing services tailored to support clients involved in human cells, tissues, and cellular and tissue-based products (HCT/Ps). Its services include testing for reproductive donors, tissue and eye banks, bone marrow and stem cells, cord blood, and blood. ViroMed Laboratories serves various sectors, including biotechnology, pharmaceuticals, medical devices, and integrated healthcare, ensuring comprehensive support for its diverse clientele.

Allied Clinical Laboratories, Inc. provides testing services to physicians, hospitals, and health care providers.

Outcomes4me Inc. is a healthcare technology company based in Cambridge, Massachusetts, founded in 2017. It has developed an AI-driven patient empowerment platform specifically designed for cancer patients, enabling them to take a proactive approach in managing their care. The platform provides personalized, evidence-based treatment options and real-time clinical information, facilitating informed decision-making and improving patient outcomes. By connecting patients with healthcare providers and offering resources related to breast cancer treatment and clinical trials, Outcomes4me aims to democratize healthcare and promote health equity. The company is led by a team of experienced professionals from healthcare, oncology, pharmaceuticals, and technology sectors, dedicated to generating insights that enhance care and accelerate research and access to innovative treatments.